Metsera, Inc. (NASDAQ:MTSR – Get Free Report) shares were down 6% during mid-day trading on Thursday . The company traded as low as $29.20 and last traded at $29.74. Approximately 329,691 shares changed hands during trading, a decline of 50% from the average daily volume of 657,366 shares. The stock had previously closed at $31.65.
Metsera Stock Performance
About Metsera
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
See Also
- Five stocks we like better than Metsera
- What Are Trending Stocks? Trending Stocks Explained
- Upstart’s Uptrend Is Just Getting Started: Its Time to Load Up
- Where Do I Find 52-Week Highs and Lows?
- Archer Aviation Lands BlackRock Investment—What’s Next for ACHR?
- Bank Stocks – Best Bank Stocks to Invest In
- Buffett Buys More Occidental Petroleum—Sticking to His Playbook
Receive News & Ratings for Metsera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metsera and related companies with MarketBeat.com's FREE daily email newsletter.
